Namiki Izumi

Nihon University — Japan

Medicine · Health Sciences

79h-index29.5kcitations655works6.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Liver Disease Diagnosis and Treatment(331), Hepatitis C virus research(273), Hepatocellular Carcinoma Treatment and Prognosis(210), Hepatitis B Virus Studies(195), Liver Disease and Transplantation(73)

Publications640 total

Diagnostic Accuracy of FIB-4 Index and FIB-3 Index for Advanced Fibrosis in Chronic Liver Disease and Age-Specific Thresholds
Journal of Clinical Medicine·2025· 1 citedOpen Access
Gastrointestinal Cancer Risk in Steatotic Liver Diseases: <scp>MASLD</scp> , <scp>MetALD</scp> and <scp>ALD</scp>
Alimentary Pharmacology & Therapeutics·2025· 3 cited
Effect of Pemafibrate on Metabolic Dysfunction‐Associated Steatotic Liver Disease: A Nationwide Multicenter Study
JGH Open·2025· 1 citedOpen Access
Efficacy and Safety of Tenofovir Alafenamide (TAF) and Tenofovir Disoproxil Fumarate (TDF) Followed by TAF in Chronic Hepatitis B Patients of East Asian Ethnicity Following 5 Years of Treatment
Alimentary Pharmacology & Therapeutics·2025· 4 citedOpen Access
Human Leukocyte Antigen Genotypes Affect Hepatitis B Virus Mutations Associated With Hepatocellular Carcinoma
Hepatology Research·2025
FRI-135 Pre-treatment serum IgG levels predict immune-related adverse events in HCC patients treated with atezolizumab plus bevacizumab
Journal of Hepatology·2025
Proposal of discontinuation criteria of atezolizumab plus bevacizumab after curative conversion therapy for unresectable early-to-intermediate-stage hepatocellular carcinoma: a multicenter proof-of-concept study
Journal of Gastroenterology·2025· 6 citedOpen Access
Pemafibrate improves liver biochemistry and GLOBE scores in patients with primary biliary cholangitis: Nationwide, multicenter study by the Japanese Red Cross Liver Study Group
Hepatology Research·2025· 4 cited
Long-Term Survival of Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib in Real-World Clinical Practice
Cancers·2025· 2 citedOpen Access
Colorectal Cancer Incidence in Steatotic Liver Disease (MASLD, MetALD, and ALD)
Clinical Gastroenterology and Hepatology·2025· 13 citedOpen Access
Effect of Proteinuria Before Lenvatinib Administration on Treatment Response After Atezolizumab Bevacizumab Combination Therapy
JGH Open·2025· 1 citedOpen Access
Comparable outcomes among etiologies in early‐stage hepatocellular carcinoma: Analysis of a nationwide registry in Japan
Hepatology Research·2024Open Access
Letter: Filling the Gaps—Enhancing <scp>MASLD</scp> Prognosis With Imaging, Diverse Populations and Extended Follow‐Up. Authors' Reply
Alimentary Pharmacology & Therapeutics·2024· 1 citedOpen Access
Editorial: Cardiometabolic criteria matters in <scp>MASLD</scp>—Authors' reply
Alimentary Pharmacology & Therapeutics·2024Open Access
Change in Liver Function in Durvalumab Plus Tremelimumab Treatment for Unresectable Hepatocellular Carcinoma
Anticancer Research·2024· 6 citedOpen Access
Cardiometabolic criteria as predictors and treatment targets of liver‐related events and cardiovascular events in metabolic dysfunction‐associated steatotic liver disease
Alimentary Pharmacology & Therapeutics·2024· 26 citedOpen Access
IDDF2024-ABS-0201 Long-term safety profile of tenofovir alafenamide in chronic hepatitis B patients; final 8-year results of 2 phase 3 studies
2024
IDDF2024-ABS-0208 No resistance to tenofovir alafenamide (TAF) in adult, HBeAg-positive and HBeAg-negative participants with chronic hepatitis B infection treated with TAF for up to 8 years
2024
IDDF2024-ABS-0195 Long-term efficacy of tenofovir alafenamide in HBeAg-positive and -negative chronic hepatitis B patients treated for up to 8 years in 2 phase 3 studies
2024
Ramucirumab for advanced hepatocellular carcinoma in the current real world: a Japanese single-arm study post-REACH-2 (The R-evolution study)
Investigational New Drugs·2024· 1 citedOpen Access
page 1 of 32Next →

Frequent Co-authors

Masatoshi Kudo(27), Norihiro Kokudo(18), Yutaka Matsuyama(15), Michiie Sakamoto(14), Osamu Nakashima(13), Osamu Matsui(11), Tadatoshi Takayama(11), Yonson Ku(10), Masayuki Kurosaki(9), Yasuhiro Asahina(8), Kazuomi Ueshima(8), Takafumi Ichida(8), Keisuke Hino(7), Masashi Mizokami(7), Masatoshi Makuuchi(7), Kiyoshi Hasegawa(7), Shuichi Kaneko(7), Yasuhito Tanaka(6), Masafumi Ikeda(6), Takuji Okusaka(6)